Ann Arbor, United States
ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to helping patients see the future. With a mission to develop innovative therapeutics for a range of retinal diseases and conditions, the company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway.
ONL is pioneering a new approach to preserve sight by focusing on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss – a leading cause of blindness. The company's lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways.
ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, for which the company has been granted orphan drug designation by the FDA. Additionally, the company is developing ONL1204 for geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
Founded in 2011 and headquartered in the United States, ONL Therapeutics operates in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. Despite the information of the last investment and investors being unavailable, ONL Therapeutics' focus on pioneering an entirely new approach to protecting and improving vision presents a potentially lucrative opportunity for future investors and stakeholders.
OliX Pharmaceuticals, Inc.
